Final Program

CONTENTS

Welcomes	4
Program Organising Committee	4
Meeting Secretariat	4
Local Organising Committee	4
ANZBMS AGM	4
Sponsors & Exhibitors	5
The Council of the ANZBMS 2004	6
ANZBMS Past & Present Councillors 1990 – 2004	6
ANZBMS Past Award Recipients	7
General Information	8
Social Events	8
Hotel Transfers	9
Keynote Speakers	9
Exhibition & Poster Area	10
Speaker Preparation	11
Poster Details	11
ANZBMS 2005 ASM	11
Scientific Program	12
Posters	19
Invited Speaker Abstracts	28
Oral Abstracts	39
Poster Abstracts	64
AGM Agenda	118
ANZBMS Membership List	119
Index To Presenting Authors	122

WELCOMES

Dear Colleagues,

The Annual Scientific Meeting is the single most important function of the society. It is the only forum we have for meeting as a group, challenging each other's ideas in an open forum, and discussing the vision we have for the future of our society. Please make your attendance a priority, submit your best work to this meeting, not to others, come to the microphone at the sessions and don't spare the presenters, and don't deprive young investigators the opportunity to learn by example as they tremble at the thought of asking a question.

Council members want to know what the society can do for you in terms of funding and educational support but we also ask for your support. Help the society by encouraging members of your department to attend the meeting. There are travel grants available and where possible we will do our best to assist you. Make an effort to increase the membership of the society so the diversity of intellectual activity of the society will grow and continue the tradition of a strong presence of Australia in the international arena of bone and mineral research. Please attend the Annual General Meeting so that Council can tell you about its activities and hear your views. If you do not tell us what you would like from your society we will decide for you. Keep the scientific flame a brightly lit beacon. I would like to thank the chairpersons of the POC/LOC - Edith Gardiner and Chris White - for their hard work in organising this program and with the support of the members, I am sure that this meeting has all the ingredients needed for success.

Ego Seeman President, ANZBMS

PROGRAM ORGANISING COMMITTEE

- * Rory Clifton-Bligh
- * Michael Hooper
- * Arthur Conigrave
- * Rebecca Mason
- * Edith Gardiner (Chair)
- * Chris White

MEETING SECRETARIAT

For all enquiries please contact: Ms Emma Waygood

ANZBMS 2004 ASM Secretariat

Conference Action Pty Ltd

PO Box 576 (Suite 104, 308 Pacific Highway)

CROWS NEST NSW 1585 AUSTRALIA

Telephone: +61 2 9437 9333 Facsimile: +61 2 9901 4586

Email: emma@conferenceaction.com.au

Dear Colleagues,

Welcome to the 2004 Annual Scientific Meeting of the ANZBMS held at Cypress Lakes Resort in the Hunter Valley, NSW.

Set amongst the vineyards of the Hunter Valley, Cypress Lakes Resort provides the perfect venue for this year's Scientific Meeting - for the exchange of ideas and the birth of new ones, for the presentation and discussion of data, or for meeting and relaxing with friends.

If you are also attending the Endocrine Society of Australia Clinical Weekend following our ASM, we encourage you to attend the Friday morning ANZBMS scientific sessions devoted to clinical issues and then to enjoy your free Friday afternoon in the Hunter Valley before the Friday evening session of the ESA Weekend, which will also have a strong bone theme.

A dose of academic bone and mineral medicine is recommended once a year. Cypress Lakes Resort is recommended at least once a lifetime. We look forward to your company and value your participation.

Edith Gardiner Chris White
Co-Convenor Co-Convenor

ANZBMS 2004 ASM ANZBMS 2004 ASM

LOCAL ORGANISING COMMITTEE

- * Bronwyn Crawford
- * Elisabeth Smith
- * Martin Epstein
- * Chris White (Chair)
- * Edith Gardiner

ANZBMS AGM

The Annual General Meeting of ANZBMS will be held in the Brokenback/Wattagan Rooms at Cypress Lakes Resort on Thursday, 19 August 2004 from 1745 – 1845 hours. All members are encouraged to attend. The following awards will be presented:

- Roger Melick Young Investigators Award (Sponsored by: Servier)
- Chris Nordin Young Investigators Award (Sponsored by Servier)
- Top two ANZBMS Outstanding Awards (Sponsored by: InSight & Key Pharmaceuticals)
- Christine & T Jack Martin Research Travel Grant (Sponsored by: Merck Sharp & Dohme)
- ANZBMS PhD Scholarship Award

SPONSORS & EXHIBITORS

On behalf of all participants in this Meeting, the Organising Committee would like to express their gratitude for the support received from the following companies:

PLATINUM SPONSORS

Eli Lilly Australia Merck Sharp & Dohme

GOLD SPONSOR

Aventis Pharma Pty Ltd

SILVER SPONSOR

Novartis Oncology

OTHER SPONSORS & EXHIBITORS

Aventis Pharma Pty Ltd
Boots Healthcare
Diagnostic Systems Laboratories Australia Pty Ltd
Eli Lilly Australia
Inderlec Medical Systems
InSight
Key Pharmaceuticals
Mayne Pharma
Medtel Pty Ltd
Merck Sharp & Dohme
Novartis Oncology
Osteoporosis Australia
Servier

THE COUNCIL OF THE ANZBMS 2004

President Professor Ego Seeman

President-Elect Associate Professor Jillian Cornish

Honorary Secretary Associate Professor David Findlay

Treasurer Dr Mark Forwood

Councillors Associate Professor Rebecca Mason

Associate Professor Roger Price Professor Geoff Nicholson Professor Philip Sambrook

ANZBMS PAST & PRESENT COUNCILLORS 1990 - 2004

Year	President	V President	Secretary	Treasurer	Councillors
1990 (Steering Group)	T J Martin		M Hooper		A Need, R Prince, J Eisman, I Reid, K Ibbertson, D Fraser, P Sambrook, E Seeman
1991-93 (Inaugural Council)	T J Martin		M Hooper	M Hooper	J Eisman, A Goulding, D Perry- Keen, J Wark, A Need, N Kent
1993-95	J Eisman	I Reid	N Kent	J Wark	P Sambrook, A Need, R Prince, D Perry-Keene, E Seeman
1995-97	I Reid	N Kent	J Moseley	P Ebeling	P Sambrook, A Need, R Prince, D Perry-Keene
1997-99	N Kent	P Ebeling	J Moseley	P Ebeling	R Prince, I Reid, M Hooper, H Morris, M Forwood
1999-01	P Ebeling	M Hooper	J Cornish	M Forwood	J Moseley, H Morris, E Mackie, M Zheng
2001-03	M Hooper	E Seeman	J Cornish	M Forwood	R Mason, R Price, G Nicholson, D Findlay
2003-05	E Seeman	J Cornish	D Findlay	M Forwood	R Mason, R Price, G Nicholson, P Sambrook

ANZBMS PAST AWARD RECIPIENTS

ROGER MELICK YOUNG INVESTIGATOR AWARD

1996 - Vicky Kartsogiannis

1997 - Linda Crofts

1998 - Janelle Barry

1999 - Liza-Jane Raggatt

2000 - Sandra Iuliano-Burns

Nathan Pavlos

2001 - David Good

2002 - Kun Zhu

2003 - Agatha Labrinidis

Xiaofang Wang

CHRISTOPHER NORDIN YOUNG INVESTIGATOR POSTER AWARD

1997 - Anne Nelson

Hidenori Murata

1998 - Marianne Holzherr

1999 - Tanya Uebergang

2000 - Josef Kaplan

2001 - Rebecca Jackson

2002 - Nathan Pavlos

2003 - Nicole Walsh

Rouha Granfar

CHRISTINE AND T JACK MARTIN RESEARCH TRAVEL GRANT

2002 - Catherine Middleton-Hardie

2003 - Vicky Kartsogiannis

ANZBMS OUSTANDING ABSTRACT AWARD

Field of Densitometry

2003 - Rob Will

Field of Calcium Nutrition

2003 - Amanda Devine

GENERAL INFORMATION

VENUE

Cypress Lakes Resort, Hunter Valley Corner McDonald & Thompson Roads Pokolbin NSW 2320 AUSTRALIA

Telephone: +61 2 4993 1555 Facsimile: +61 2 4993 1599

REGISTRATION DESK

The Meeting Registration Desk will be located outside the main rooms of the Convention Centre at Cypress Lakes Resort.

Registration hours:

Wednesday, 18 August 2004 0730 – 1800 hours Thursday, 19 August 2004 0800 – 1800 hours Friday, 20 August 2004 0830 – 1310 hours

NAME BADGES

All delegates will be given a name badge at registration. For security reasons, we ask that you wear your name badge at all times. This name badge is also the official entrance pass to all scientific sessions, exhibition area, poster area, teas & lunches each day and inclusive social functions.

MESSAGES

All messages received during the Meeting will be displayed on the message board near the registration desk.

SMOKING POLICY

There will be no smoking in all scientific sessions or in areas where food and beverage are served.

HOTEL ACCOUNTS

All delegates are reminded to pay their hotel account prior to departure from their hotel. Please note that the deposit you have paid on the ANZBMS 2004 ASM registration form has been credited to your room account, however, each delegate is responsible for the payment of incidentals and any further room costs.

CREDIT CARDS

Credit cards accepted at the Registration Desk are Mastercard, Australian Bankcard and Visa – please note that American Express & Diners will not be accepted.

MOBILE PHONES

Please ensure that all mobile phones are switched to silent mode during the scientific sessions.

DISCLAIMER OF LIABILITY

The Meeting Organising Committee reserves the right to amend any part of the Meeting program or event should it be necessary.

The Australian & New Zealand Bone & Mineral Society, including the Meeting Secretariat, will not accept liability for damages of any nature sustained by participants or their accompanying persons, or loss of, or damage to, their personal property as a result of the 2004 Annual Scientific Meeting or related events.

SOCIAL EVENTS

WELCOME RECEPTION

Venue: Exhibition & poster area

Date: Wednesday, 18 August 2004

Time: 1830 – 2030 hours

Cost: Included in Full Delegate Registration Fee

Extra tickets: \$50.00 per person

It is hoped all delegates and partners will be able to attend this evening, which will be held in the exhibition & poster area.

FUN RUN

Sponsored by: Merck Sharp & Dohme Date: Thursday, 19 August 2004

Time: 0700 - 0800 hours

All participants are asked to meet just outside the reception area of Cypress Lakes Resort by 0700 hours. Lincoln Amidy from Pinnacle Corporate Health will give you a brief on course and go through a few stretches with you. The 5km course will be indicated by markers on trees and on the ground. Please ensure that you are suitably dressed for the run and advise Lincoln of any health issues prior to starting the run. The course will conclude back at Cypress Lakes Resort on the grass area outside the Convention Centre.

GALA DINNER

Sponsored by: Osteoporosis Australia

Venue: Tamburlaine Winery
Date: Thursday, 19 August 2004

Time: 1930 - 2300 hours

(pre-dinner drinks 1930 – 2000 hours)Included in Full Delegate Registration Fee

Extra tickets: \$90.00 per person

The Gala Dinner featuring local wines will be held at Tamburlaine Winery, which is located across the road from Cypress Lakes Resort, Hunter Valley. A Cypress Lakes Resort shuttle bus will ferry people to Tamburlaine between 1915 – 1945 hours – however it is only a short walk across the road to Tambulaine. We hope all delegates and their guests will join us on this occasion to make it a memorable evening.

HOTEL TRANSFERS

The following transfers to/from the ASM have been organised for those delegates not staying at Cypress Lakes Resort:

Wednesday, 18 August 2004

- * 0745 hours Harrigan's Hunter Valley Gardens Cypress Lakes Resort
- * 2015 hours Cypress Lakes Resort Hunter Valley Gardens - Harrigan's

Thursday, 19 August 2004

- * 0800 hours Harrigan's Hunter Valley Gardens Cypress Lakes Resort
- * 1845 hours Cypress Lakes Resort Hunter Valley Gardens - Harrigan's
- * 1930 hours Harrigan's Hunter Valley Gardens Tamburlaine Winery
- * 2230 hours Tamburlaine Winery Hunter Valley Gardens - Harrigan's

Friday, 20 August 2004

* 0830 hours - Harrigan's - Hunter Valley Gardens - Cypress Lakes Resort

The distance between Cypress Lakes Resort and Hunter Valley Gardens/Harrigan's Irish Pub is about a 5 minute drive, but a 20 minute walk.

Therefore, if you would like to utilise these transfers, please wait at the hotel lobby of the particular property at the above times for collection.

KEYNOTE SPEAKERS

GERARD KARSENTY

Baylor College of Medicine, Houston, Texas, USA

Dr Gerard Karsenty is Professor of Molecular and Human Genetics at Baylor College of Medicine. His research focuses on two main areas. One is transcriptional control of osteoblast differentiation and how it relates to the pathophysiology of human skeletal dysplasias. In this line of research, his laboratory has uncovered the role of the key transcription factor Runx2 in this process. A second line of research focuses on a genetic approach of skeletal physiology with an emphasis on the molecular basis of the spatial restriction of extracellular matrix mineralization to bone and on the control of bone mass by humans and the nervous Professor Karsenty's groundbreaking elucidated key research has identified and mechanisms that control bone formation, providing a number of significant novel insights into bone biology and physiology.

SUNDEEP KHOSLA

Mayo Clinic, Rochester, Minnesota, USA

Dr Sundeep Khosla is Professor of Medicine and Research Chair in the Division of Endocrinology, Metabolism, and Nutrition, Mayo Clinic College of Medicine. His research focuses on clinical-investigative studies aimed at defining the pathogenesis of age-related bone loss in women and in men. In addition, he is also pursuing studies at a more basic level on the mechanisms of sex steroid action on bone. Dr Khosla is a member of the Council of the American Society for Bone and Mineral Research and is also on the Board of Directors of the US National Osteoporosis Foundation.

INVITED INTERNATIONAL SPEAKER

SERGE FERRARI

University Hospital, Geneva, Switzerland

Dr Ferrari is a Swiss National Science Foundation (SNF) Professor of Medicine in the Division of Bone Diseases, Department of Rehabilitation and Geriatrics at the University Hospital in Geneva, Switzerland. He currently serves as a consultant in genetics for the Framington Osteoporosis Study, is a member of the Board of Directors of the Centers for Genetics, Nutrition, Exercise & Health from the International Union of Nutritional Sciences (IUNS), a member of the Editorial Board of Osteoporosis International and a consultant for numerous drug companies interested in the development of antiosteoporosis drugs and molecular markers osteoporosis risk. His research aims to identify candidate gene polymorphisms for osteoporosis in humans, with a particular interest in their interaction with environmental factors. Dr Ferrari also investigates the regulation of bone mass acquisition and PTH activity in transgenic models.

INVITED SATELLITE MEETING SPEAKER

FRANK RAUCH

Shores Hospital, Montreal, Canada

Dr Frank Rauch is Assistant Professor at the Department of Paediatrics at McGill University and Assistant Director of Clinical Research at The Shriner's Hospital for Children in Montreal. Dr Rauch has developed significant expertise in bone histomorphometry in children and in children receiving interventional therapy for metabolic bone disease. His research interests are in skeleton development and metabolic bone disorders in children and he has published extensively in both these fields. His talks at the Paediatric Bone Meeting in Sydney will include "What the heck is bone density?" and "Why are bisphosphonates such useful drugs in osteogenesis imperfecta?".

EXHIBITION & POSTER AREA

The Exhibition and Poster Area will be open during the following times:

Wednesday, 18 August 2004	1030 - 2030 hours
Thursday, 19 August 2004	0830 - 1800 hours
Friday, 20 August 2004	0830 - 1100 hours

Please find below a current floor plan of the area.

We acknowledge with gratitude the support given by these companies and ask that you show your appreciation by visiting all the exhibits.

Stand	Company
4 & 5	Inderlec Medical Systems
6 & 7	Aventis Pharma
8	Medtel Pty Ltd
9	Key Pharmaceuticals
10 & 11	Merck Sharp & Dohme
12 & 13	Eli Lilly Australia
14	Novartis Oncology
17	Mayne Pharma
18	InSight
20	Diagnostic Systems Laboratories

SPEAKER PREPARATION

Speakers are asked to check their audio visual material before presenting. There will be an audio visual technician at the back of each room for the duration of the Meeting and we ask that you check-in with this technician at least two hours prior to your presentation. At this time you will be able to provide the technician with a copy of your presentation.

POSTER DETAILS

All posters will be displayed for the duration of the Meeting. All posters should be in place prior to 1030 hours on <u>WEDNESDAY</u>, <u>18 AUGUST 2004</u> and removed by 1100 hours (morning tea) on <u>FRIDAY</u>, <u>20 AUGUST 2004</u>. No responsibility will be taken for posters left after this time.

Presenting authors are asked to stand by their poster(s) at the following times:

ODD numbers:

1245 – 1315 hours, Wed, 18 Aug 2004 (lunchtime) 1745 – 1830 hours, Wed, 18 Aug 2004 (poster rounds B)

EVEN numbers:

1700 – 1745 hours, Wed, 18 Aug 2004 (poster rounds A) 1245 – 1315 hours, Thur, 19 Aug 2004 (lunchtime)

NOVARTIS 1/2 PAGE ADVERT

ANZBMS 2005 ASM

Mark your diaries now!

The ANZBMS 2005 ASM is to be held:

Date: 7 – 9 September 2005

Venue: InterContinental Burswood Resort

Location: Perth

All ANZBMS members and 2004 ASM delegates will automatically receive information once it is available. However, if you do have any queries, please contact the ANZBMS 2005 ASM Secretariat:

Ms Emma Waygood Conference Action Pty Ltd PO Box 576 (Suite 104, 308 Pacific Highway) CROWS NEST NSW 1585 AUSTRALIA

Telephone: +61 2 9437 9333 Facsimile: +61 2 9901 4586

Email: emma@conferenceaction.com.au

SCIENTIFIC PROGRAM

WEDNESDAY, 18 AUGUST 2004

(All sessions today will be plenary style and located in the Convention Centre at Cypress Lakes Resort)

0730 - 1800		Registration
0815 - 0830		Welcome
0830 - 1030		SESSION 1 - HORMONAL CONTROL OF BONE Chaired by: Rachel Davey & Jill Cornish
0830 - 0915	IP1	Sex hormones & the skeleton Sundeep Khosla
0915 - 0940	IP2	Insights from ERKO models: what do they tell us about estrogen receptor function in bone? Natalie Sims
0940 - 1030		FREE ORALS
0940 - 0950	O1	Osteoclast inhibitory lectin (OCIL) is required for normal bone remodelling in vivo and inhibits osteoblast function in vitro <u>Akira Nakamura</u> , JMW Quinn, NA Sims, CT Gange, H Zhou, V Kartsogiannis, EH Allan, TJ Martin, KW Ng & MT Gillespie
0950 - 1000	O2	Thrombin stimulates osteoclast differentiation by activation of protease-activated receptor-1 Sutharshani Sivaguranathan, PD Campbell, R Smith, CN Pagel, RN Pike & EJ Mackie
1000 - 1010	O3	Inhibition of breast cancer growth in bone using TRAIL therapy Lee Thai, A Labrinidis, S Hay, V Liapis, S Bouralexis, K Weldon, BJ Coventry, DM Findlay & A Evdokiou
1010 - 1020	O4	Targeting primary prevention of fracture in osteoporotic women: Geelong osteoporosis study Mark Kotowicz, MJ Henry, JA Pasco, KM Sanders, E Seeman & GC Nicholson
1020 - 1030	O5	Bone resorption and osteoporotic fractures in elderly men: the Dubbo osteoporosis epidemiology study Christian Meier, TV Nguyen, JR Center, MJ Seibel & JA Eisman
1030 - 1100		Morning tea
1100 - 1300		SESSION 2 - YOUNG INVESTIGATOR AWARDS Sponsored by: Servier Chaired by: David Findlay
1100 - 1115	O6	Identification and functional characterization of an osteoclast-derived osteoblastic factor (ODOF): novel growth factor in bone Tony Phan, R Han, V Smuts, MH Zheng & J Xu
1115 - 1130	O7	Y-receptor and leptin interactions in the central regulation of bone formation and marrow fat Susan Allison, PA Baldock, A Sainsbury, RF Enriquez, M Couzens, H Herzog & EM Gardiner
1130 - 1145	O8	Gene expression in the Pagetic osteoblast Usha Bava, D Naot, KE Callon, IR Reid, R Pitto, S McCowan, T Cundy & J Cornish
1145 - 1200	O9	Controversies in calcium-sensing in bone

Shaimaa Atwa, TC Brennan, AD Conigrave & RS Mason

1200 - 1215	O10	Zoledronic acid treatment does not delay the process of endochondral ossification in a rat fracture model Michelle McDonald, SK Dulai & DG Little
1215 - 1230	O11	Sesquiterpene lactone parthenolide blocks lipopolysaccharide induced osteolysis via the suppression of NF-kB activity Kirk Ho Man Yip, MH Zheng, HT Feng, JH Steer, DA Joyce & J Xu
1230 - 1245	O12	Functional responses of bone cells to stimulation by strontium Tara Brennan, MM Muir, AD Conigrave & RS Mason
1245 - 1300	O13	Secretory phospholipase- A_2 (sPLA ₂) inhibition prevents ovariectomy-induced bone loss in adult rats Laura Gregory, WL Kelly & MR Forwood
1300 - 1430		Lunch and trade displays / posters odd nos.
1430 - 1630		SESSION 3 - CURRENT ASPECTS OF BONE BIOLOGY Chaired by: Eleanor Mackie & John Eisman
1430 - 1500	IP3	Osteoblast differentiation Gerard Karsenty
1500 - 1530	IP4	Regulation of bone development - blind genes vs functional adaptation Frank Rauch
1530 - 1600	IP5	PTH and arrestins Serge Ferrari
1600 - 1630	IP6	The bone remodelling compartment: a possible coupling structure Erik Eriksen
1630 - 1700		Afternoon tea
1700 - 1830		SESSION 4 - POSTER SESSION
1700 - 1745		Poster rounds A (EVEN poster numbers)
1745 - 1830		Poster rounds B (ODD poster numbers)
1830 - 2030		Welcome Reception Exhibition & poster area

THURSDAY, 19 AUGUST 2004

0700 - 0800		Fun Run Sponsored by: Merck Sharpe & Dohme
0800 - 1800		Registration
0830 - 1030		SESSION 5 - BODY COMPOSITION AND BONE MASS (Brokenback/Wattagan/Sugarloaf Rooms, Convention Centre, Cypress Lakes Resort) Chaired by: Richard Prince & Rory Clifton-Bligh
0830 - 0900	IP7	Body weight and bone density Ian Reid
0900 - 0925	IP8	Growth hormone, IGFs and bone: a promise yet unfulfilled Sundeep Khosla
0925 - 0950	IP9	Y receptors in the central control of bone Paul Baldock
0950 - 1000		FREE ORAL
	O14	An association study of BMP4 polymorphisms in postmenopausal women shows effects on bone mass Richard Prince , L Rameshbabu, SG Wilson, IM Dick, FMA Islam & A Devine
1000 - 1030		Morning tea
1030 - 1200		SESSION 6 - CONCURRENT FREE ORALS (including keynote presentations)
		Basic: (Brokenback/Wattagan Rooms, Convention Centre, Cypress Lakes Resort) Chaired by: Mark Forwood & Gerald Atkins
1030 - 1040	O15	PTHrP as a mediator of DNA repair in cancer Matthew Gillespie, N Ilievska, S Bouralexis, RJ Thomas & TJ Martin
1040 - 1050	O16	Essential role for SIAH1A, but not SIAH2, ubiquitin ligase in bone growth and remodelling Natalie Sims, IJ Frew, JMW Quinn, CR Walkley, RA Dickins, LE Purton, DDL Bowtell & MT Gillespie
1050 - 1100	O17	Dietary omega-3 oils stimulate bone formation in vivo Howard Morris, A Moore, A Mulaibrahimovic, LG Cleland & MJ James
1100 - 1110	O18	M-CSF promotes proliferation of human osteoclast precursors but inhibits resorption by mature osteoclasts and is not necessary for resorption activity <u>Iason Hodge</u> , MA Kirkland & GC Nicholson
1110 - 1120	O19	Three-dimensional morphology of crack growth in cortical bone: implications for bone quality Julia Kuliwaba, KH Zarrinkalam, MAB Wallwork, B Martin & NL Fazzalari
1120 - 1130	O20	Tartrate-resistant acid phosphatase and cathepsin K promoters used to drive CRE recombinase expression in osteoclasts in transgenic mice Maria Chiu, JF McManus, AJ Notini, AI Cassady, JD Zajac & RA Davey
1130 - 1200	IP10	Keynote Presentation - Genetic manipulation of human bone marrow stromal stem cells for enhanced regeneration of skeletal tissues Stan Gronthos

	Clinic	eal:
		(Sugarloaf/Bimbadeen Rooms, Convention Centre, Cypress Lakes Resort) Chaired by: Kong-Wah Ng & Kerrie Sanders
1030 - 1040	O21	The effect on behaviour and bone mineral density of individualised bone mineral density feedback and educational interventions in premenopausal women: a randomised controlled trial Tania Winzenberg, B Oldenburg, M Riley, S Frendin, L De Wit & G Jones
1040 - 1050	O22	Playing golf is associated with increased vertebral bone size and mass in post menopausal women Shona Bass, J Cook, K Singleton, J Black & RM Daly
1050 - 1100	O23	The heavier they are, the harder they fall? Julie Pasco, MJ Henry, EN Merriman, GC Nicholson & MA Kotowicz
1100 - 1110	O24	Ethnic differences in effect of calcium supplementation on bone density in peripubertal girls in a double-blind, placebo-controlled randomised trial Christine Rodda , M Urdampilletta, J Hu, B Strauss, E Briganti & C Gilfillan
1110 - 1120	O25	Hormone replacement therapy and measures of hip strength: a co-twin analysis Lynda Paton, T Beck, C Nowson, C Margerison, L Semanick, S Kantor & JD Wark
1120 - 1130	O26	Early experience of bisphosphonate use in adolescents with osteonecrosis David Little , RR Brown, E Goergens & CT Cowell
1130 - 1200	IP11	Keynote Presentation – The material and structural basis of bone strength: the anatomy of fracture prevention by remodelling suppressants Ego Seeman Sponsored by: Aventis
1200 - 1330		Lunch and trade displays / posters even nos.
1230 - 1315		Lunchtime workshop on clinical audits (Brokenback/Wattagan Rooms, Convention Centre, Cypress Lakes Resort) Sponsored by: Merck Sharp & Dohme Chaired by: Graeme Jones
	O27	The bone protection project: an audit of in hospital investigation and management of osteoporosis following minimal trauma fracture (MTF) Chris Gilfillan
	O28	RPAH first fracture clinic Lesley Sullivan
1330 - 1535		SESSION 7 - CONTROL OF BONE MINERALISATION (Brokenback/Wattagan/Sugarloaf Rooms, Convention Centre, Cypress Lakes Resort) Chaired by: Markus Seibel & Matthew Gillespie
1330 - 1415	IP12	Genetic determinants of the spatial restriction of extracellular matrix mineralisation Gerard Karsenty
1415 - 1535		FREE ORALS
1415 - 1425	O29	OPG mutations that cause idiopathic hyperphosphatasia impair OPG protein secretion Dorit Naot, CA Middleton-Hardie, H Cundy, IR Reid, T Cundy & J Cornish
1425 - 1435	O30	L-amino acid regulation of parathyroid hormone secretion Arthur Conigrave, H-C Mun, L Delbridge, M Wilkinson, SJ Quinn & EM Brown

1435 - 1445	O31	IL-13 inhibits osteoclast differentiation and enhances dendritic cell formation in human CFU-GM cultures Matthew Constable, JM Hodge, CJ Aitken, CM Lopez & GC Nicholson
1445 - 1455	O32	Lactoferrin receptors and signalling pathways in osteoblasts Amy Zhu, A Grey, T Banovic, K Callon, M Watson, J Bracegirdle, K Palmano, IR Reid & J Cornish
1455 - 1505	O33	Bone density relevance and interpretation in Caucasian children aged 9 – 16 years of age: insights from a population based fracture study $\underline{\text{Graeme Jones}} \ \& \ D \ \text{Ma}$
1505 - 1515	O34	Asymptomatic vertebral deformity as major risk factor for subsequent fractures and mortality: a 14-year prospective study Tuan Nguyen , C Pongchaiyakul, ND Nguyen, JR Center & JA Eisman
1515 - 1525	O35	Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial Leon Flicker, R MacInnis, M Stein, S Scherer, K Mead, C Nowson, J Thomas, C Lowndes, JL Hopper & JD Wark
1525 - 1535	O36	The femoral neck is ellipsoid. Assumption of circularity introduces errors in FN volume, volumetric bone mineral density and bone strength Roger Zebaze, F Welsh, S Iuliano-Burns, A Evans, J Konstantynowicz & E Seeman
1535 - 1600		Afternoon tea
1600 - 1740		SESSION 8 - CONCURRENT FREE ORALS (including keynote presentations)
		Basic: (Brokenback/Wattagan Rooms, Convention Centre, Cypress Lakes Resort) Chaired by: Colin Dunstan & Rebecca Mason
1600 - 1610	O37	Vitamin D metabolism in human osteoblasts <u>Gerald Atkins</u> , PH Anderson, K Welldon, ACW Zannettino, PD O'Loughlin, HA Morris & DM Findlay
1610 - 1620	O38	Prostaglandin E ₂ mediates IL-6 production by thrombin-stimulated osteoblasts Charles Pagel, S-J Song, L-H Loh, S Merlin, E Tudor, RN Pike & EJ Mackie
1620 - 1630	O39	Hydrogen peroxide accelerates human osteoclast differentiation and up-regulates thioredoxin Michelle Chacksfield, JM Hodge, CJ Aitken & GC Nicholson
1630 - 1640	O40	Expression of tenascin-w as a potential tenascin-c replacement in the skeleton of tenascin-c knockout mice Brad Morrison, A Scherberich, R Chiquet-Ehrismann, CN Pagel & EJ Mackie
1640 - 1650	O41	N-acetylcysteine inhibits human osteoclast differentiation via modulation of the thioredoxin system Nicola Zimmerman, CJ Aitken, JM Hodge & GC Nicholson
1650 - 1700	O42	Generation of a calcitonin receptor (CTR) LOXP mouse line for targeted deletion in osteoclasts Rachel Davey, JF McManus, AJ Moore, WSM Chiu, AJ Notini, HA Morris, DM Findlay & JD Zajac
1700 - 1710	O43	The effect of lactoferrin on RANKL and OPG mRNA levels in bone cells Pak Cheung Tong, D Naot, U Bava, JM Lin, M Watson, KE Callon, IR Reid & J Cornish

1710 - 1740	IP13	Keynote Presentation – The immune system and bone remodelling Matthew Gillespie
		<u>Clinical:</u> (Sugarloaf/Bimbadeen Rooms, Convention Centre, Cypress Lakes Resort) Chaired by: Kathy Briffa & Geoff Nicholson
1600 - 1610	O44	Prediction of hip fracture in the elderly by fall-related factors Nguyen Dinh Nguyen, C Pongchaiyakul, JR Center, JA Eisman & TV Nguyen
1610 - 1620	O45	Genetic and environmental contributions to hip strength: in female twins aged 18 and over John Wark, L Paton, TJ Beck, L Semanick, S Kantor, R The & C Nowson
1620 - 1630	O46	The characteristics of bone fractures in Polish adolescents aged 16 - 20 years. Anthropometric, constitutional and environmental conditions Jerzy Konstantynowicz, I Bialokoz-Kalinowska, R Motkowski, P Abramowicz, J Piotrowska-Jastrzebska, J Sienkiewicz & E Seeman
1630 - 1640	O47	Balance performance, muscle strength and gait function in women: effects of genes and environment Natalie El Haber, K Hill, A-M Cassano, JS Cui, R MacInnis, JL Hopper & JD Wark
1640 - 1650	O48	Mechanosensitivity of the femoral neck in females is not increased during the adolescent growth spurt Mark Forwood, DA Bailey, TJ Beck, RL Mirwald, ADG Baxter-Jones & K Uusi-Rasi
1650 - 1700	O49	Quantitative ultrasound of the calcaneus but not biochemical markers of bone turnover are associated with fractures in frail older people with vitamin D deficiency: the FREE study Philip Sambrook , JS Chen, MJ Seibel, LM March, ID Cameron & RG Cumming
1700 - 1710	O50	Loss of femoral neck bone mass with rapid weight loss is more strongly related to baseline fat mass than change in body composition Kerrie Sanders, GK Kiroff & GC Nicholson
1710 - 1740	IP14	Keynote Presentation - Structural and material basis of bone strength and its decay Nick Fazzalari
1745 - 1845		Annual General Meeting (Brokenback/Wattagan Rooms, Convention Centre, Cypress Lakes Resort)
1930 - 2300		Gala Dinner Sponsored by: Osteoporosis Australia Tamburlaine Winery

FRIDAY, 20 AUGUST 2004

(All sessions today will be plenary style and located in the Convention Centre at Cypress Lakes Resort)

0830 - 1310		Registration
0900 - 1030		SESSION 9 - SKELETAL MALIGNANCY AND METABOLIC BONE DISEASE Sponsored by: Novartis Chaired by: Chris Cowell & Michael Hooper
0900 - 0930	IP15	Treatment of advanced prostate cancer Fred Saad
0930 - 1000	IP16	TNF family members and malignancy Colin Dunstan
1000 - 1030	IP17	Bisphosphonate use in orthopaedic therapies David Little
1030 - 1100		Morning tea
1100 - 1310		SESSION 10 - OSTEOPOROSIS THERAPIES Sponsored by: Eli Lilly Chaired by: Mark Kotowicz
1100 - 1130	IP18	Molecular mechanisms in anabolic therapy Jack Martin
1130 - 1200	IP19	Wnt/LRP5 mutations and osteoporosis Serge Ferrari
1200 - 1230	IP20	Treatment of osteoporosis in women – why, whom, when, what drug? Ego Seeman
1230 - 1300	IP21	Monitoring osteoporosis treatment Markus Seibel
1300 - 1310		Concluding remarks Ego Seeman
1310 - 1350		Lunch
1400		Coaches depart for Sydney

POSTERS

В	A	S	I	C

- P1 ANALYSIS OF HYPERTROPHY AND PHYSIOLOGICAL CELL DEATH IN THREE-DIMENSIONAL CULTURES OF EQUINE FOETAL CHONDROCYTES

 Yasser Ahmed, L Tatarczuch, K Alkhodair, CN Pagel & EJ Mackie
- P2 COMPARISON OF OSTEOARTHRITIC AND NORMAL TRABECULAR BONE FROM THE INTERTROCHANTERIC REGION OF THE PROXIMAL FEMUR BY cDNA MICROARRAY ANALYSIS Blair Hopwood, S Gronthos, JS Kuliwaba, DM Findlay & NL Fazzalari
- P3 CYCLOOXYGENASE-2 (COX-2) INHIBITION PREVENTS OVARIECTOMY-INDUCED BONE LOSS IN ADULT RATS

 Laura Gregory, WL Kelly & MR Forwood
- P4 SYNTHESIS OF 1,25(OH)D₃ IN OSTEOBLASTS: AN AUTOCRINE OR PARACRINE ROLE Paul Anderson, K Welldon, DM Findlay, HA Morris & GJ Atkins
- P5 **25-HYDROXYVITAMIN** D₃-1α-HYDROXYLASE PROMOTER ACTIVITY IN THE RAT OSTEOBLAST-LIKE CELL LINE ROS 17/2.8

 Andrew Turner, PP Dwivedi, PH Anderson, BK May & HA Morris
- P6 ENDOCYTOSIS OF LACTOFERRIN BY OSTEOBLASTS

 Maureen Watson, KE Callon, A Zhu, JM Ross, IR Reid, D Naot, AB Grey & J Cornish
- P7 **OSTEOCLAST RESORPTION OF HYDROXYAPATITE BONE SUBSTITUTE MATERIALS** H Lucas, H Zreiqat, KA Gross, C Holding, DM Findlay, M Wallwork & <u>David Haynes</u>
- P8 PARATHYROID HORMONE PEPTIDE (1-34) DERIVED FROM THE JAPANESE PUFFER FISH STIMULATES BONE FORMATION IN YOUNG MALE RATS

 Julie McManus, JD Zajac, NA Sims, A Axell, WSM Chiu, AJ Notini, RA Davey, HE MacLean & JA Danks
- P9 MODIFIED AND UN-MODIFIED GELATINE SPONGES AS A SCAFFOLD FOR OSTEOBLASTS CELLS Ramin Rohanizadeh, MV Swain & RS Mason
- P10 TRANSGENIC MICE OVER-EXPRESSING 11&-HYDROXYSTEROID DEHYDROGENASE TYPE 2 (11&HSD2)
 UNDER THE COL1a(I) PROMOTER PROVIDE A MODEL TO TEST DIRECT EFFECTS OF EXOGENOUS
 CORTICOSTEROIDS ON OSTEOBLASTS
 KJ Brennan, H Zhou, J de Winter, Colin Dunstan & MJ Seibel
- P11 MODEL-INDEPENDENT 3D DESCRIPTORS OF CANCELLOUS BONE QUALITY: AN IMPROVED EXPLANATORY MODEL FOR A SURROGATE OF TRABECULAR STRENGTH
 I Parkinson, Nick Fazzalari & P Sutton-Smith
- P12 STUDIES ON TRANSCRIPTION FACTORS EXPRESSED DURING ENDOCHONDRAL OSSIFICATION OF EQUINE ARTICULAR-EPIPHYSEAL GROWTH CARTILAGE
 Khalid Alkhodair, Y Ahmed, CN Pagel & EJ Mackie
- P13 IS INCREASED BONE TURNOVER CONTRIBUTING TO HUMAN FEMORAL FRACTURES? H Tsangari, Julia Kuliwaba, DM Findlay & NL Fazzalari
- P14 **TRANSACTIVATION RESPONSE OF VDRB1 IS PROMOTER- CELL- AND LIGAND-SPECIFIC**Colette Fong, LM Esteban, SJ Allison, JL Flanagan, D Amr, C Liddle, JA Eisman & EM Gardiner
- P15 MUTATIONAL ANALYSIS CLARIFIES MECHANISM FOR DISTINCT TRANSACTIVATION PROPERTIES OF THE VITAMIN D RECEPTOR, VDRB1
 Luis Esteban, SJ Allison, C Fong, JL Flanagan, JA Eisman & EM Gardiner

P16	PATTERNS OF PHYSIOLOGICAL CELL DEATH IN EQUINE HYPERTROPHIC CHONDROCYTES
	Liliana Tatarczuch, K Alkhodair, YA Ahmed & EJ Mackie

- P17 **DEVELOPMENT AND USE OF AN ANTIBODY TO FGF23**Michiko Mirams, BG Robinson, R Clifton-Bligh, RS Mason & AE Nelson
- P18 LIMITED EXPOSURE OF OSTEOBLASTS TO HIGH DOSES OF ZOLEDRONIC ACID DOES NOT ADVERSELY AFFECT CELL SURVIVAL OR OSTEOGENIC DIFFERENTIATION

 Aaron Schindeler, C Godfrey, M McDonald & DG Little
- P19 WITHDRAWN
- P20 THE EFFECTS OF EXOGENOUS GALANIN APPLICATION ON BONE FORMATION IN MOUSE CALVARIA Aaron McDonald, JA Schuijers, AL Gundlach & BL Grills
- P21 GALANIN AND GALANIN RECEPTOR EXPRESSION IN UMR106.01 CELLS May Yao, JA Schuijers, P-J Shen, AL Gundlach & BL Grills
- P22 NOVEL ACTIVATORS OF THE CALCIUM-SENSING RECEPTOR ACTIVATE RENAL CALCIUM AND WATER EXCRETION
 Hiu Chuen Lok & AD Conigrave
- P23 RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B (RANK) AND TUMOUR NECROSIS FACTOR ALPHA (TNFα) EXPRESSION IN TISSUES OBTAINED FROM SITES OF PERI-IMPLANT OSTEOLYSIS CHARACTERISED BY COMPUTED TOMOGRAPHY (CT)

 Christopher Holding, KR Shrestha, K Dharmapatni, R Stamenkov, DW Howie, DM Findlay, MA McGee, GJ Atkins & DR Haynes
- P24 INTERACTION OF GTP-BINDING RAB3D WITH TCTEX-1, A LIGHT CHAIN OF THE CYTOPLASMIC DYEIN MICROTUBULE MOTOR COMPLEX

 Nathan Pavlos, J Xu, A Carrello, K Kroeger, K Ednet & MH Zheng
- P25 OSTEOSCLEROSIS IN MICE LACKING RAB3D IS RELATED TO DISRUPTIONS IN POST-TGN VESICLE TRAFFICKING IN OSTEOCLASTS

 Nathan Pavlos, J Xu, D Riedel, SL Teitelbaum, R Jahn, FP Ross & MH Zheng
- P26 A HUMAN OSTEOCLAST FORMING CO-CULTURE ACW Zannettino, <u>Tina Vincent</u>, P Kostakis, K Welldon, DM Findlay & GJ Atkins
- P27 INTERACTION BETWEEN WNT SIGNALLING PATHWAY AND 1,25(OH)₂D₃ IN OSTEOBLAST-LIKE MC3T3-E1 CELLS
 Yanchuan Shi, JA Eisman & EM Gardiner
- P28 EVIDENCE OF RECIPROCAL REGULATION BETWEEN THE HIGH EXTRACELLULAR CALCIUM AND RANKL SIGNAL TRANSDUCTION PATHWAYS IN RAW CELL DERIVED OSTEOCLASTS

 Jiake Xu, C Wang, R Han, N Pavlos, T Phan, JH Steer, AJ Bakker, DA Joyce & MH Zheng
- P29 THE CALCINEURIN-INHIBITOR TACROLIMUS (FK506) IS A POTENT SUPPRESSOR OF HUMAN OSTEOCLAST DIFFERENTIATION

 Carolina Lopez, JM Hodge, MJ Constable, CJ Aitken & GC Nicholson
- P30 GENE EXPRESSION PROFILING IN CALLUS TISSUE FROM PATIENTS WITH NEUROFIBROMOTOSIS 1-ASSOCIATED PSEUDOARTHROSIS OF THE TIBIA Elisabeth Smith, EM Gardiner, N Elmonoufy, CE Johnston II & R Welch
- P31 FOUR NOVEL MUTATIONS IN THE CALCIUM-SENSING RECEPTOR ASSOCIATED WITH FAMILIAL HYPOCALCIURIC HYPERCALCAEMIA

 Inge Stewart, N Lewis, A McElduff, D Chipps, A Poynten, P Clifton-Bligh, A Conigrave, B Robinson & R Clifton-Bligh

CLINICAL

P46

P47

WITHDRAWN

CLINIC	<u>CAL</u>
P32	CALCIUM ABSORPTION AND VITAMIN D METABOLITES IN HIP FRACTURE SUBJECTS Allan Need, M Metz, PD O'Loughlin, M Horowitz & BEC Nordin
P33	BONE MINERAL AND BONE SIZE: COMPARISONS OF PREPUBERTAL PACIFIC ISLAND AND EUROPEAN CHILDREN LIVING IN NEW ZEALAND Andrea Grant, FK Gordon, EL Ferguson, SM Williams, T-E Henry, VM Toafa, BE Guthrie & A Goulding
P34	SITE-SPECIFIC BONE CHANGES OF YOUNG MILK-AVOIDERS OVER TWO YEARS JEP Rockell, SM Williams, RW Taylor, AM Grant, IE Jones & Ailsa Goulding
P35	SKELETAL AGE DEVIATION: ASSOCIATION WITH BONE MASS AND FRACTURE RISK IN CHILDREN Graeme Jones & D Ma
P36	AUTOSOMAL DOMINANT PATTERN OF INHERITANCE IN AN AUSTRALIAN FAMILY WITH LOW BONE MINERAL DENSITY Christian Meier, M Kennerson, G Nicholson & MJ Seibel
P37	A COMPARISON OF HEALTHY, YOUNG ADULT MALE VERSUS FEMALE BROADBAND ULTRASOUND ATTENUATION OF THE CALCANEUS VIA QUANTITATIVE ULTRASOUND ANALYSIS BK Weeks & Belinda Beck
P38	PERSISTENCE WITH RISEDRONATE TREATMENT IN THE ACTNOW TM PATIENT SUPPORT PROGRAMME <u>James Robertson</u> & S McKechnie
P39	GENDER DIFFERENCES IN RELATIONSHIPS BETWEEN BODY COMPOSITION COMPONENTS, THEIR DISTRIBUTION AND BONE MINERAL DENSITY: AN OPPOSITE SEX TWIN STUDY Joanna Makovey, P Sambrook & V Naganathan
P40	IMPLEMENTATION OF AN EVIDENCE-BASED PHYSIOTHERAPY SERVICE FOR OSTEOPOROSIS Thorlene Egerton, SL Mitchell & G Creed
P41	DETAILED ANALYSIS OF RISK FACTORS FOR BONE LOSS IN AN AUSTRALIAN CROHN'S DISEASE (CD) POPULATION Naomi Lee, G Radford-Smith, J Wong, M Forwood & D Taaffe
P42	SIMILAR TRUNK LENGTH BUT SHORTER LEG LENGTH IN CHINESE THAN CAUCASIANS IMPLICATION FOR RACIAL DIFFERENCES IN HIP FRACTURE RATES XF Wang, Yunbo Duan & E Seeman
P43	THE FRACTURE RISK INDEX AND BMD AS PREDICTORS OF VERTEBRAL STRUCTURAL FAILURE Yunbo Duan, F Duboeuf, F Munoz, PD Delmas & E Seeman
P44	INTRA-VERTEBRAL BONE MINERAL DENSITY ASSESSMENT USING DXA: A PILOT STUDY Andrew Briggs, JD Wark, S Kantor, N Fazzalari, AM Greig & KL Bennell
P45	INTRA-RATER AND INTER-RATER PRECISION OF MEASURING APPARENT BONE MINERAL DENSITY IN VERTEBRAL SUBREGIONS USING SUPINE LATERAL DUAL ENERGY X-RAY ABSORPTIOMETRY (DXA) IN VIVO
	Andrew Briggs, JD Wark, S Kantor, R Son Teh, AM Greig & KL Bennell

EDUCATING MOTHERS CAN ALTER CHILDREN'S OSTEOPOROSIS PREVENTIVE BEHAVIOURS

<u>Tania Winzenberg</u>, B Oldenburg, S Frendin, L De Wit & G Jones

- P48 EVALUATION OF A PHARMACIST PERFORMING OSTEOPOROSIS SCREENING IN RURAL PHARMACIES USING QUANTITATIVE HEEL ULTRASOUND (QUS)

 M Naunton, GM Peterson & Graeme Jones
- P49 ZOLEDRONIC ACID PRODUCES HIGHER AND MORE RAPID THERAPEUTIC RESPONSE RATES VERSUS RISEDRONATE IN PATIENTS WITH PAGET'S DISEASE

 Ian Reid, J Brown, D Hosking, W Fraser, K Lyles, P Hunt, NS Levitt, G Tsoukas, P Richardson, M Luchi, Y Saidi, G Su, K Zelenakas & P Miller
- P50 INCREASED BODY WEIGHT IN PRIMARY HYPERPARATHYROIDISM: IMPLICATIONS FOR DISEASE ASSOCIATIONS

 Mark Bolland, AB Grey, GD Gamble & IR Reid
- P51 ANTI-EPILEPTIC DRUG USERS HAVE AN INCREASED RELATIVE PROPORTION OF ABDOMINAL FAT AS DETERMINED BY DUAL ENERGY X-RAY ABSORPTIOMETRY (DEXA): A USAGE-DISCORDANT FEMALE TWIN AND MATCHED SISTER STUDY

 Sandra Petty, L Paton, S Kantor, TJ O'Brien & JD Wark
- P52 BONE DENSITY, FRACTURES AND THE DEFINITION OF OSTEOPOROSIS Chris Nordin
- P53 LONGITUDINAL STUDY OF BONE-RELATED BIOCHEMICAL VARIABLES ACROSS THE MENOPAUSE

 Chris Nordin, JM Wishart, PM Clifton, R McArthur, F Scopacasa, AG Need, HA Morris, PD O'Loughlin & M

 Horowitz
- P54 THE MINERAL MASS AND EXTERNAL DIMENSIONS OF THE FEMORAL NECK ARE DISSOCIATED BECAUSE OF THE DIFFERING BEHAVIOUR OF THE PERIOSTEAL AND ENDOCORTICAL ENVELOPES Roger Zebaze, G Maalouf & E Seeman
- P55 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTRE EVALUATION OF THE EFFICACY AND SAFETY OF ZOLEDRONATE (4MG THREE MONTHLY), ADMINISTERED INTRAVENOUSLY, TO PATIENTS WITH β-THALASSAEMIA-ASSOCIATED OSTEOPAENIA: 12 MONTH INTERIM ANALYSIS

 Christopher Gilfillan, BI Strauss, C Rodda, D Bowden, A-M Kean, M Obaid & B Crawford
- P56 FRAGILITY FRACTURES IN FRANKSTON: THE FAILURE OF MANAGEMENT OF OSTEOPOROSIS IN OUTER METROPOLITAN MELBOURNE
 K Ouick, S Varadarajan, D Dutta, S Morris & Christopher Gilfillan
- P57 BALANCE, GAIT AND STRENGTH CHANGES IN 45-78 YEAR OLD HEALTHY WOMEN: A FOLLOW UP STUDY

 Natalie El Haber, K Hill, A-M Cassano, LM Paton, R MacInnis, JL Hopper & JD Wark
- P58 THE EFFECT OF AN INPATIENT FRACTURE PROTOCOL ON PRESCRIPTION OF OSTEOPOROSIS THERAPY

 Sandi Warr, T Greenaway, E Francis & G Jones
- P59 IN VIVO PRECISION OF DXA-DERIVED HIP STRUCTURAL ANALYSIS VARIABLES UNDER CLINICAL CONDITIONS: COMPARISON WITH CONVENTIONAL BMD USING IDENTICAL DXA SCANS Ben Khoo, TJ Beck & RI Price
- P60 CONVERSION OF LUNAR SPINE BMD TO HOLOGIC UNITS AT NON STANDARD VERTEBRAL REGIONS OF INTEREST
 Beverley White, M Hooper, M Henry, G Nicholson & N Pocock

P61	LIMITED RESIDUAL BENEFITS OF CALCIUM SUPPLEMENTATION ON BONE MASS ACCRUAL IN PREPUBERTAL CHILDREN ONE YEAR AFTER THE CESSATION OF TREATMENT Sandra Iuliano-Burns, A Evans, X-F Wang, S Matthews & E Seeman
P62	TRENDS IN PREVALENCE OF OSTEOPOROSIS IN SOUTH AUSTRALIA AND EFFECT ON QUALITY OF LIFE T Gill, A Taylor, P Phillips, G Leach & Pauline Kelly
P63	BONE STIFFNESS REDUCTION ASSOCIATED WITH REMODELING OF ADULT EQUINE P1 BONE MEASURED BY ULTRASOUND SPEED Zafrir Bechor, S Toulson, B Kehoe, EJ Mackie & HMS Davies
P64	SITE AND TIMING OF BONE RESPONSE TO TURNING EXERCISE IN THE DISTAL FORELIMB OF ADULT HORSES Zafrir Bechor, J Merritt & HMS Davies
P65	EVALUATION OF A CARE PATHWAY TO IMPROVE THE DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS IN PATIENTS WITH LOW TRAUMA FRACTURE J Whitham, C Gibb, Pauline Kelly & J Pink
P66	DECREASED FEMORAL NECK BONE DENSITY WITH INCREASED NECK SECTION MODULUS, A DECADE FOLLOWING ATTAINMENT OF PEAK BONE DENSITY; A PROSPECTIVE HIP STRUCTURAL ANALYSIS STUDY Roger Price, NK Briffa, TJ Beck, AL Mein, BCC Khoo, RL Prince & SS Dhaliwal
P67	A LONGITUDINAL STUDY OF EXERCISE EFFECTS ON BONE MASS AND STRUCTURE IN PRE-AND EARLY- PUBERTAL FEMALE NOVICE DANCERS AND CONTROLS Bernadette Matthews, KL Bennell, HA McKay, KM Khan & JD Wark
P68	"DANCING FOR BONE HEALTH": A 3-YEAR LONGITUDINAL STUDY OF EXERCISE EFFECTS ON BONE MINERAL ACCRUAL ACROSS PUBERTY IN FEMALES Bernadette Matthews, KL Bennell, HA McKay, KM Khan, ADG Baxter-Jones, RL Mirwald & JD Wark
P69	COMPARISON OF LOWER LIMB STRENGTH, BALANCE, GAIT STABILITY VALUES BETWEEN ASIAN AUSTRALIAN AND CAUCASIAN AUSTRALIAN WOMEN TN Hutabarat, N El Haber, EL Bond, K Hill, Lynda Paton & JD Wark
P70	PRECISION AND ACCURACY OF AUTOMATED VERSUS MANUAL HIP STRENGTH ANALYSIS IN YOUNG ADULTS

Cynthia Ong, HG Ahlborg, TV Nguyen & NA Pocock

P71 CONCORDANCE OF AUTOMATED AND MANUAL HIP GEOMETRY ESTIMATION IN OLDER ADULTS Cynthia Ong, TV Nguyen & NA Pocock

P72 COMPARABILITY OF NORMATIVE PAEDIATRIC BONE DENSITY DATA Julie Briody, M Henry, A Goulding, G Jones, R Howman-Giles & N Pocock

- INTER MANUFACTURER CONVERSION OF L2-L4 BONE DENSITY IN THE PAEDIATRIC POPULATION P73 Madeleine Thompson, J Briody, R Howman-Giles & N Pocock
- P74 SAFETY AND EFFICACY OF IMI CHOLECALCIFEROL FOR VITAMIN D DEFICIENCY Terry Diamond, P Rohl & M Meerkin
- P75 OSTEOPOROSIS AND SPINAL FRACTURES IN MEN WITH PROSTATE CANCER: RISK FACTORS AND THE EFFECTS OF ANDROGEN DEPRIVATION THERAPY Terry Diamond, J Bucci, JH Kersley, P Aslan, WB Lynch & C Bryant

P76	VITAMIN D AND PARATHYROID HORMONE LEVELS PREDICT FALLS RISK IN OLDER WOMEN Meaghan Read, GC Nicholson, MA Kotowicz, JA Pasco & KM Sanders
P77	QUANTIFICATION OF METAPHYSEAL REMODELLING IN CHILDREN TREATED WITH BISPHOSPHONATES David Little, K Ward & CT Cowell
P78	BONE TURNOVER MARKERS IN ELDERLY MEN AND THEIR RELATIONSHIPS TO PROSPECTIVE CHANGE IN BONE MINERAL DENSITY Tuan Nguyen, C Meier, JR Center, JA Eisman & M Seibel
P79	EFFECTS OF BISPHOSPHONATES ON HIP FRACTURE RISK REDUCTION: A BAYESIAN ANALYSIS OF CLINICAL TRIALS Nguyen Nguyen, JA Eisman & TV Nguyen
P80	IMPACT OF WITHIN-SUBJECT VARIABILITY ON THE ASSESSMENT OF CHANGE IN BONE TURNOVER MARKERS Tuan Nguyen, C Meier, JR Center, JA Eisman & M Seibel
P81	LONG-TERM BONE LOSS IN MEN AND WOMEN: EFFECTS OF QUADRICEPS STRENGTH AND BODY WEIGHT Tuan Nguyen, ND Nguyen, JR Center & JA Eisman
P82	SMOKING AS A MAJOR OSTEOPOROSIS RISK FACTOR AMONG IRANIAN AUSTRALIAN WOMEN Azam Baheiraei, NA Pocock, JE Ritchie, JA Eisman & TV Nguyen
P83	A CAUSAL MODEL ANALYSIS AND OSTEOPOROSIS PREVENTION <u>Azam Baheiraei</u> , JE Ritchie, JA Eisman & TV Nguyen
P84	THE CLINICAL EFFICACY OF THREE-DIMENSIONAL RECONSTRUCTIONS OF TWO-DIMENSIONAL MR IMAGES: EVALUATION IN A SIMULATED TIBIAL PLATEAU DEPRESSION FRACTURE MODEL Andrew Kurmis & JP Slavotinek
P85	WITHDRAWN
P86	BONE MASS AND ESTROGEN RECEPTOR STATUS IN WOMEN WITH BREAST CANCER Kerrie Sanders, B Ekanayake, GC Nicholson, MJ Henry, MA Kotowicz, JA Pasco & DA Watters
P87	BARRIERS TO EFFECTIVE MANAGEMENT OF OSTEOPOROSIS IN MODERATE AND MINIMAL TRAUMA FRACTURES: A PROSPECTIVE STUDY Dana Bliuc, CR Ong, JA Eisman & JR Center
P88	BMD-INDEPENDENT CONTRIBUTION OF HIP STRENGTH INDICES TO HIP FRACTURE RISK IN ELDERLY MEN AND WOMEN Henrik Ahlborg, ND Nguyen, TV Nguyen, JR Center & JA Eisman
P89	DESIGN AND PERFORMANCE TESTING OF A NEW BONE-EQUIVALENT CORTICAL SHELL PHANTOM: COMPARATIVE MEASUREMENTS OF ITS STRUCTURAL GEOMETRY DERIVED FROM DXA AND pQCT Ben Khoo, TJ Beck, B Turk & RI Price
P90	DEPRESSION AND BONE MINERAL DENSITY IN A COMMUNITY SAMPLE: GEELONG OSTEOPOROSIS STUDY

Felice Jacka, JA Pasco, MJ Henry, MA Kotowicz, GC Nicholson & M Berk

D Hughes, B White, B Crawford & Michael Hooper

CLINICAL EXPERIENCE WITH ZOLEDRONIC ACID IN OSTEOPOROSIS

P91

	<u>Julie Pasco</u> , MJ Henry, HG Schneider, GC Nicholson & MA Kotowicz
P93	FRACTURE RISK ASSOCIATED WITH BONE MINERAL DENSITY: A PROSPECTIVE STUDY Julie Pasco, MJ Henry, EN Merriman, GC Nicholson, E Seeman & MA Kotowicz
P94	TOLERABILITY AND RENAL SAFETY OF INTRAVENOUS ZOLEDRONIC ACID IN BENIGN METABOLIC BONE DISEASE D Hughes, K Sommer, J Hetherington, Bronwyn Crawford & M Hooper
P95	LIFETIME PARTICIPATION IN IMPACT SPORTS IS AN IMPORTANT DETERMINANT OF BONE SIZE AND STRENGTH, BUT NOT BMD, IN OLDER MEN Sonja Kukuljan, RM Daly, SL Bass & C Nowson
P96	A NEW DOSING CONCEPT FOR BISPHOSPHONATE THERAPY: RATIONALE AND DESIGN OF THE MONTHLY ORAL IBANDRONATE IN LADIES (MOBILE) STUDY Peter Ebeling, RK Will, J Graham, AG Need, RR Recker, JY Reginster & B Bonvoisin
P97	MUSCLE-BONE RELATIONSHIP IN ABLE-BODIED AND IMMOBILISED INDIVIDUALS Prisca Eser, S Bass, R Daly & H Schiessl
P98	ANDROGEN RECEPTOR CAG REPEAT POLYMORPHISM AND BONE DENSITY: A FAMILY AND CASE-CONTROL ASSOCIATION STUDY IN MEN WITH PRIMARY OSTEOPOROSIS Z Hussein, JA Ellis, A Lamantia, K Greenland, S Yeung, ZYH Wong, SB Harrap, JD Zajac & Peter Ebeling
P99	DECREASED AREAL AND VOLUMETRIC BONE MINERAL DENSITY (BMD) IN MEN WITH PRIMARY OSTEOPOROSIS AND THEIR FIRST-DEGREE MALE RELATIVES: EVIDENCE FOR A FAMILIAL EFFECT ON BONE ACQUISITION B Erbas, S Ristevski, C Poon, S Yeung & Peter Ebeling
P100	SURGEON/PHYSICIAN JOINT MANAGEMENT OF FRACTURED HIP INPATIENT MANAGEMENT REVIEW J Thwaites, F Mann, A Rothwell, C Frampton & Nigel Gilchrist
P101	EFFECTIVENESS OF THE CLINICAL PATHWAY FOR FRACTURED NECK OF FEMUR Nigel Gilchrist, J McKie, J Thwaites, K Wilson, J Gapes, D Jones, S Newman, P Larking & N Gibson
P102	ESTABLISHED OSTEOPOROSIS PATIENTS - DO BONE REPORTS AND RECOMMENDATIONS ALTER PATIENT MANAGEMENT? Nigel Gilchrist, A Heard, P Maguire, R March & P Reilly
P103	ANTIOXIDANT SUPPLEMENTS AND MARKERS OF BONE TURNOVER IN NON-SMOKING WOMEN: GEELONG OSTEOPOROSIS STUDY LK Wilkinson, Julie Pasco, MJ Henry, HG Schneider, GC Nicholson & MA Kotowicz
P104	PROTEIN CONSUMPTION IS AN IMPORTANT DETERMINANT OF LOWER LIMB BONE MASS IN ELDERLY WOMEN Amanda Devine, RL Prince, FMA Islam, SS Dhaliwal & IM Dick
P105	LOW BODY WEIGHT IS ASSOCIATED WITH INCREASED INCIDENT FRACTURE RISK IN OLDER WOMEN Rakhshanda Naheed, A Devine, I Dick & RI, Prince

β-BLOCKERS REDUCE BONE RESORPTION MARKER IN PERIMENOPAUSAL WOMEN: GEELONG

P92

P106

IN OLDER POSTMENOPAUSAL WOMEN

Ian Dick, A Devine & RL Prince

OSTEOPOROSIS STUDY

ENDOGENOUS ESTRADIOL IS ASSOCIATED WITH RENAL CALCIUM AND PHOSPHATE HANDLING

- P107 PREVALENT OSTEOPOROTIC FRACTURE IS ASSOCIATED WITH INCREASED INCIDENT OSTEOPOROTIC FRACTURE RISK IN OLDER WOMEN

 Amanda Devine, I Dick, R Naheed & RL Prince
- P108 INCIDENCE OF HIP FRACTURES RESULTING IN SURGERY IN AUSTRALIA Vanessa Wells, A Esterman & TC Hearn
- P109 A NON-CLINICAL TRIAL ASSESSMENT OF MEDICATIONS USED IN THE TREATMENT OF OSTEOPOROSIS

 Sam Korn, JA Pasco, MJ Henry GC Nicholson & MA Kotowicz
- P110 RATIONALE FOR INTERMITTENT INTRAVENOUS IBANDRONATE INJECTIONS IN POSTMENOPAUSAL OSTEOPOROSIS

 Philip Sambrook, RL Prince, MJ Hooper, JA Eisman, P Miller, RR Recker, S Adami, B Bonvoisin & RC Schimmer
- P111 PARADIGM OF CARTILAGE REGENERATION BY MATRIX-INDUCED AUTOLOGOUS CHONDROCYTE IMPLANTATION (MACI): A HISTOLOGICAL ASSESSMENT

 Ming-Hao Zheng, C Willers, L Kirilak, J Xu, D Wood & A Shimmin